MASCC News

MASCC Society News October 2019

2019    In the October 2019 issueMASCC President Dr. Rajesh Lalla announces MASCC's most recent affiliation agreement with the Associação de Investigação e Cuidados de Suporte em Oncologia (AICSO) of Portugal. We bring you exciting news about the new MASCC Recommendations for the Management of Constipation in Patients with Advanced Cancer and a detailed description of the upcoming 2019 Cancer Treatment-Related Adverse Events Symposium at Memorial Sloan Kettering Cancer Center. Also, in this issue, we begin an exploration of MASCC and Social Media with "Part I: Why Social Media Matters."  As usual, we include several conference reminders and deadlines. We extend a warm welcome to new members who joined us in August. And we encourage every member to be a voice for MASCC!

Survey Participants Wanted: Practitioners' Views on PROs

2019    MASCC’s Survivorship Study Group invites healthcare professionals involved in the care of cancer patients to share their experiences and perceptions regarding patient-reported outcomes (PROs) in a 10-minute online survey. The Study Group is investigating oncology practitioners' current strategies and experiences in applying PROs in clinical practice, performance measurement, and research. The aims are (1) to explore practitioners’ experiences and perceptions on the use of PROs in routine clinical care at the patient level and (2) to assess the value of PROs as a performance or quality-of-care indicator at the system level. This study has been approved by the Institutional Review Boards of Chinese University of Hong Kong, and the Edith Cowan University, Western Australia.
If you are interested in participating, please follow this link for more information and the online survey by July 31, 2020: Patient-Reported Outcomes (PRO) Data Collection in Routine Care: An International Survey of Oncology Practitioners.

2019 Cancer Treatment-Related Adverse Events Symposium

2019    The 2019 Annual Cancer Treatment-Related Adverse Events Symposium will be held on Friday, October 25, 2019 and Saturday, October 26, 2019 at the Rockefeller Research Laboratories, 430 East 67th Street, New York, NY. The course is directed by MASCC member Mario E. Lacouture, MD, who is the Director of the Oncodermatology Program at Memorial Sloan Kettering Cancer Center.

Read More

MASCC and Social Media. Part 1: Why Social Media Matters

2019    Social media is the process whereby people use online tools and platforms to share content and information. Social media platforms include websites where users share, exchange, discuss, and sometimes create or modify content (in the form of text, images, audio and video) in virtual communities on the Internet.

Read More

MASCC Recommendations for the Management of Constipation in Patients with Advanced Cancer

2019    Constipation is a common problem among patients with advanced cancer, with a reported prevalence of 32–87% in this group, in whom it also causes significant morbidity. Opioid-induced constipation appears to be a chronic side effect and is more common in patients with cancer pain than in those with nonmalignant pain. It may be influenced by the type of opioid involved, as well as by genetic factors, but does not appear to be particularly influenced by the dose of opioid.

Read More

AICSO - A New MASCC Affiliate

2019    MASCC has just signed an affiliate agreement with the Associação de Investigação e Cuidados de Suporte em Oncologia (AICSO), the Oncology Supportive Care Research Association in Portugal. AICSO Board member Dr. Andreia Capela has been instrumental in bringing about this partnership, which will increase the memberships of both organizations, support collaboration, and help to promote the goals of supportive care in cancer. AICSO, founded in 2001, is a nonprofit, public interest institution. Its aim is the integration of supportive care resources for cancer patients all along the cancer continuum. In recent years, the organization has been active in promoting an active lifestyle for all patients living with and beyond cancer. To meet its goals, AICSO promotes research programs and professional development in supportive cancer care, as well as helping to educate the public about the importance of supportive care for all cancer patients and survivors. AICSO is led by President Dr. Ana Joaquim and Vice-President Dr. Sandra Custódio who, as well as Dr. Capela, are medical oncologists. Find out more at http://www.aicso.pt.

Read More

MASCC Society News September 2019

2019    In the September 2019 issue, we bring you exciting news about two clinical practice guidelines: a new MASCC/ISOO/ASCO Clinical Practice Guideline on Medication-Related Osteonecrosis of the Jaw, and the latest update of the MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy. We announce the 2019 Best of MASCC India meeting, joint sessions featuring MASCC at both EONS and ESMO, and educational programs in supportive and palliative care at the MD Anderson Cancer Center. MASCC President Dr. Rajesh Lalla discusses the importance of clinical practice guidelines to the MASCC mission. As usual, we include several conference reminders and deadlines. We extend a warm welcome to new members who joined us in July. And we encourage every member to be a voice for MASCC!

Joint Sessions at ESMO and EONS

2019    Don’t miss these joint sessions at upcoming meetings!

Read More

MASCC/ISOO 2019 Meeting Slides and Videos

2019    Presentation slides and select session videos which include speaker slides and audio from our 2019 Annual Meeting in San Francisco are available on the MASCC website. (Member login required)

Read More

23rd Annual Conference on Supportive Care, Hospice, and Palliative Medicine at the MD Anderson Cancer Center

2019    The 23rd Annual Interdisciplinary Conference on Supportive Care, Hospice, and Palliative Medicine will be held October 18-19, 2019 at the MD Anderson Cancer Center in Houston, Texas, USA. Palliative and supportive cancer care are critical to the delivery of optimal care to cancer patients. Many clinicians are unaware of the need for whole-patient care from symptom management to quality of life beyond the treatment of the primary disease. Caring for the cancer patient in the advanced stages of disease is especially challenging and includes medical, psychosocial, ethical, and spiritual dimensions. The conference will help participants learn how to implement new techniques and treatments in clinical practice to improve patient care and outcomes. (Complimentary registration for September 2019 Board Review Attendees!)

Read More

Supportive and Palliative Care Education at the MD Anderson Cancer Center

2019    Updates in Hospice and Palliative Medicine and Intensive Physician Board Review, September 24-26, 2019

Read More

2019 Best of MASCC, India

2019    The second Best of MASCC India Meeting, hosted by the Indian Association of Supportive Care in Cancer (IASCC), will be held September 14-15 at Tata Memorial Hospital, Mumbai. The program will include presentations, workshops, and discussions on treatments and techniques for minimizing the symptoms and side effects of cancer and its treatments, including the psychological, social, and economic dimensions of cancer diagnosis and treatment. The meeting is intended for physicians, nurses, and other oncology professionals. For more information about the program, faculty, and registration, see Best of MASCC/IASCC 2019 or contact [email protected].

Read More

MASCC at ESMO and EONS

2019    MASCC will have an exhibit at the 2019 Congress of the European Society for Medical Oncology (ESMO) and the European Nursing Society (EONS), both of which take place September 27th to October 1st in Barcelona, Spain. If you are there, please stop by and say hello at Booth S21 in the Society Village!

2019 Update: MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy

2019    MASCC’s Mucositis Study Group (MSG) has announced the latest update of the MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy. An editorial by MSG Chair Sharon Elad, DMD, MSc, and seven articles have just been published (July 2019) in a Special Section of Supportive Care in Cancer (SCC). This is the first set of papers generated as part of this guideline update and it represents several types of interventions for oral mucositis: anti-inflammatory agents; photobiomodulation; vitamins, minerals, and nutritional supplements; and protocols categorized as basic oral care.

Read More

MASCC Society News August 2019

2019    In the August 2019 issue, we introduce MASCC’s newest affiliate, the Russian Society of Supportive Care in Oncology. MASCC President Dr. Rajesh Lalla discusses efforts to grow MASCC membership. We also focus on neurological complications of cancer and its treatment with a profile of the Neurological Complications Study Group, led by Drs. Maryam Lustberg and Alex Chan, as well as a research highlight on risk factors for chemotherapy-induced peripheral neuropathy. A second research highlight summarizes the work of Dr. Maryam Lustberg and her colleagues on early detection of anthracycline-induced cardiotoxicity in breast cancer survivors. As usual, we include several conference reminders and deadlines. We extend a warm welcome to new members who joined us in June. And we encourage every member to be a voice for MASCC! 

Early Detection of Anthracycline-Induced Cardiotoxicity

2019    Anthracycline therapy is a mainstay for breast cancer and many other cancers, but it is associated with a rate of incident heart failure more than five times the average. Preclinical studies of anthracycline-induced myocardial damage show that the substrate for heart failure is myocardial fibrosis preceded by myocardial edema or inflammation. Loss of endothelial progenitor cells (EPCs) may also contribute to myocardial damage. The detection of early changes via blood biomarkers is challenging. However, recently, cardiac magnetic resonance (CMR) has been successfully used to detect post-treatment anthracycline-induced fibrosis through T1 mapping, paralleling a decline in left ventricular ejection fraction (LVEF).

Read More

Research on Chemotherapy-induced Peripheral Neuropathy

2019    Alex Molassiotis and Alex Chan are among the co-authors of a recent study of risk factors for chemotherapy-induced peripheral neuropathy (CIPN) among patients receiving taxane-based and platinum-based chemotherapy.1 CIPN is a significant side effect of neurotoxic chemo-therapies and one that is difficult to manage. Although several risk factors for CIPN have been identified, methodological limitations in much past research limit knowledge about such risks. Molassiotis and his colleagues undertook this study to assess the relative contributions of a wider range of potential risk factors than previously studied.

Read More

Neurological Complications Study Group Profile

2019    Chair Maryam B. Lustberg, MD, MPH, is a Medical Oncologist and tenured Associate Professor in the College of Medicine at The Ohio State University and a member of the Cancer Control Program at The Ohio State University’s James Comprehensive Cancer Center (OSUCCC). She has specialized in breast cancer and works as a medical oncologist at the Stefanie Spielman Comprehensive Breast Center. She is the Director of Breast Cancer Survivorship and the Medical Director of Cancer Supportive Care Services at OSUCCC and physician champion for the Adolescent and Young Adult Program. She has led numerous clinical trials, including research on the early detection of heart damage in patients treated with chemotherapy. She was recently awarded an R01 from the National Cancer Institute on focused on targeted therapies for the prevention of chemotherapy-induced neuropathy. Maryam has authored or co-authored of numerous research papers on such topics as physicians’ perspectives on survivorship care for older breast cancer survivors, prevention of chemotherapy-induced peripheral neuropathy, and early detection of chemotherapy induced cardiotoxicity in breast cancer survivors. She is a member of the American Society of Clinical Oncology (ASCO) Neuropathy Task Force and the ASCO Survivorship Education Track, and member of Alliance and Southwest Oncology Group Cooperative Group Networks in the USA. In addition to the Neurological Complications Study Group, Maryam is a member of MASCC Study Groups on Nutrition and Cachexia and Survivorship.

Read More

Russian Society of Supportive Care in Oncology

2019    As Dr. Rajesh Lalla noted in his President’s Message in our July issue, MASCC has recently signed an affiliation agreement with the Russian Society of Supportive Care in Oncology (RASSC). RASSC is led by Dr. Anton Snegovoy, Chairman of the Board, and Dr. Inessa Kononenko, Executive Director. The affiliation includes the reciprocal agreement that all members of RASSC automatically become MASCC members and all current MASCC members residing in the Russian Federation become members of RASSC.

Read More

New Clinical Practice Guideline on MRONJ

2019    A new MASCC/ISOO/ASCO Clinical Practice Guideline on Medication-Related Osteonecrosis of the Jaw has been published in the Journal of Clinical Oncology (JCO) by the American Society of Clinical Oncology. (Yarom N et al, J Clin Oncol 2019 Jul 22:JCO1901186. Epub ahead of print). 

Read More